The ATTC network, established in 2018 with funding from the UKRI Medicines Manufacturing Challenge through Innovate UK, has forged close partnerships with the NHS and industry to bolster NHS capacity for delivering advanced therapies to patients. Collaborative efforts have notably improved clinical trial infrastructure, offering patients invaluable access to potentially life-changing treatments, particularly those with limited options or rare diseases.

The UK is a world leader in clinical research with 175 ongoing advanced therapy trials being carried out here, and with 9% of global ATMP trials having representation in the UK[1]. However many more products are in development and further action is needed to ensure that the NHS can deliver advanced therapies to patients at scale across the UK and that the UK maintains its position as a globally attractive location for clinical research.

Through funding from the National Institute for Health and Care Research (NIHR), and in close collaboration with NIHR infrastructure and its counterparts in the devolved administrations, the ATTC network aims to build upon its existing work, expand its reach, and integrate its initiatives into standard practice. The primary focus will be on enhancing the readiness of advanced therapy clinical trials, with the goal of expanding capacity and capability across a broader network to bring more innovative therapies to patients and strengthen the UK’s appeal to industry. This will be accomplished through a series of interconnected initiatives, each addressing persistent barriers in the field:

[1] CGT Catapult ATMP Clinical Trials Database 2023 highlights

Looking for more information?

Find details of how to contact us here